GlucoTrack, Inc. (GCTK) AI Stock Analysis
GCTK AI stock analysis summary
AI ResearchGlucoTrack, Inc. (GCTK) is a medical device company developing non-invasive glucose monitoring devices for diabetes management. For the trailing twelve months ended June 30, 2026, the company generated $0 in revenue and posted an eps_ttm of -$123.15. Its stock closed at $0.72 on October 16, 2026, following a 1-year return of -99.3%.
- Market cap
- $738,062
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- -99.3% S&P 500 16.8%
- Avg. target
- —
Bull case
- GlucoTrack maintained net cash of $1.1M as of June 30, 2026, supported by minimal total debt of $19,000.
- The stock trades at a price-to-book multiple of 0.6x as of October 16, 2026.
- The company's beta of 0.73 indicates lower historical volatility relative to the broader market.
Bear case
- The company generated $0 in revenue over the trailing twelve months ended June 30, 2026, with an eps_ttm of -$123.15.
- GlucoTrack posted a 1-year stock return of -99.3%, substantially underperforming the S&P 500 return of 16.8%.
- Shareholders experienced substantial dilution, reflected by a 5-year share count increase of 2057.3%.
What GlucoTrack does
GlucoTrack, Inc., headquartered in Or Yehuda, Israel, is a medical device firm that designs, develops, and distributes non-invasive glucose monitoring devices. Founded in 2001 and formerly known as Integrity Applications, Inc., the company rebranded in November 2021. Its flagship product is the GlucoTrack glucose monitoring device, engineered to provide pain-free blood glucose readings for people with diabetes and pre-diabetes. Operating with 15 employees, the company focuses on international expansion and technological innovation to help patients manage their health through user-friendly medical devices.
Growth and profitability
GlucoTrack experienced shifting revenue across its reported fiscal years, posting $611,689 in FY2016 and $589,462 in FY2017 before revenue fell to $43,488 in FY2018. Revenue rose to $208,000 in FY2019 before declining 66.0% to $70,778 in FY2020. Between FY2015 and FY2020, revenue recorded a 5-year compound annual growth rate of -13.1%. The company operated at consistent net losses, including net income of -$5.4M in FY2016 and -$2.7M in FY2020. In the trailing twelve months through June 30, 2026, revenue stood at $0, with an operating margin of 0.0% and an eps_ttm of -$123.15.
Balance sheet and cash flow
As of June 30, 2026, GlucoTrack held $1.1M in cash and short-term investments against total debt of $19,000, leaving net cash of $1.1M. Total assets were $1.5M, while shareholders' equity stood at -$1.7M, marking a negative equity position. The company's current ratio was 0.46. In FY2025, capital expenditures were $96,000, and the company recorded a 5-year share count change of 2057.3%.
Valuation and performance
GlucoTrack closed at $0.72 on October 16, 2026, giving it a market cap of $738,062 and an enterprise value of $2.5M. The stock trades at a price-to-sales ratio of 527.0x and an EV to revenue multiple of 420.9x, compared to a median price-to-sales of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 0.6x. Over the past year, GCTK delivered a return of -99.3%, compared to a 16.8% return for the S&P 500. Over five years, the stock returned -100.0% versus an 83.0% gain for the index.
What analysts expect
GlucoTrack does not have analyst coverage, ratings counts, or consensus price targets reported. The company's next earnings date is November 12, 2026. The stock last closed at $0.72 on October 16, 2026, near its 52-week low of $0.70 and below its 52-week high of $112.50. The shares trade -95.0% relative to their 200-day moving average, with a beta of 0.73.
Key risks and what to watch
- Liquidity pressure is indicated by a current ratio of 0.46 as of June 30, 2026.
- Shareholders' equity stands at -$1.7M, leaving the company with a negative equity balance.
- Short interest represents 12.0% of the float, pointing to notable negative market positioning.
- Historical revenue contracted at a compound annual rate of -13.1% from FY2015 to FY2020.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this GCTK AI stock analysis
This page is an AI-written research summary of GlucoTrack, Inc. (GCTK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: GCTK income statement, GCTK balance sheet, GCTK key metrics, GCTK chart. See the GCTK stock overview for the latest quote and news.
GCTK AI stock analysis FAQ
Does GlucoTrack pay a dividend?
No, GlucoTrack does not pay a dividend.
What was GlucoTrack's trailing twelve month revenue?
For the trailing twelve months ended June 30, 2026, GlucoTrack generated $0 in revenue with an eps_ttm of -$123.15.
When is GlucoTrack's next earnings release?
GlucoTrack's next earnings date is scheduled for November 12, 2026.
How much cash and debt does GlucoTrack have?
As of June 30, 2026, GlucoTrack had $1.1M in cash and short-term investments and $19,000 in total debt, resulting in net cash of $1.1M.
How has GCTK stock performed over the past year?
Over the past year, GCTK recorded a return of -99.3%, trailing the S&P 500 return of 16.8%.